---
document_datetime: 2023-09-21 17:05:23
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/twinrix-adult-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: twinrix-adult-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 2.0314847
conversion_datetime: 2025-12-19 06:07:21.901182
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 01 February 2004 please refer to module 8B .

- The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application for a Type I variation relating to the filling process, which will be carried out at an alternative  site  -  Sächsische  Serumwerke,  Dresden,  Germany.  The  EMEA  adopted  a  positive opinion  on  23  July  1997  and  no  amendments  to  the  Annexes  of  the  Community  Marketing Authorisation were required.
- The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application for a Type II variation relating to an additional presentation, where separate sterile needles are included with the pre-filled syringes (without needle). This new presentation applies to all package sizes. The EMEA adopted a positive opinion on 23 July 1997. The Commission Decision  amending  the  Community  Marketing  Authorisation  was  adopted  on  17  November 1997.
- The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application for a Type I variation relating to the monograph, in which the set limit for unbound hepatitis A antigen has been modified in line with the performance of the ELISA used to test for the completeness of adsorption.  The EMEA adopted a positive opinion on 24 September 1997 and no amendments to the Annexes of the Community Marketing Authorisation were required.
- The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application  for  a  Type  I  variation  relating  to  the  new  Manufacturing  Authorisation  Holder, SmithKline  Beecham  Biologicals  Manufacturing  S.A,  located  in  Wavre  Belgium,  which performs labelling and packaging of the medicinal product. The EMEA notified the European Commission and the MAH on 31 October 1997 that the variation is accepted.
- The MAH submitted in accordance with Article 10(3)  of  Council  Directive  No.  92/27/EE,  a notification of a change to an aspect of the Package Leaflet not connected to the Summary of Product  Characteristics.  The  EMEA  notified  the  European  Commission  and  the  MAH  on  29 October 1998 that the change is accepted. The Commission Decision amending the Community Marketing Authorisation was adopted on 22 December 1998.
- The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application for a Type I variation relating to an extension of shelf-life of the finished product from 24 months to 36 months at 2 - 8 ˚ C. The EMEA notified the European Commission and the  MAH  on  6  November  1998  that  the  variation  is  accepted.  The  Commission  Decision amending the Community Marketing Authorisation was adopted on 26 January 1999.
- The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application  for  a  Type  I  variation  relating  to  a  new  subcontracted  packaging  site  located  in Mayenne,  France.  The  EMEA  notified  the  European  Commission  and  the  MAH  on  31 December 1998 that the variation is accepted.
- The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application for a Type I variation relating to the introduction of a new HAB in-house reference vaccine. The EMEA adopted a positive opinion on 25 March 1999 and no amendments to the Annexes of the Community Marketing Authorisation were required.
- The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application  for  a  Type  I  variation  to  replace  of  the  pre-filled  glass  syringe  with  one  which consists  of  a  longer  barrel  and  a  longer  plunger  rod.  The  EMEA  notified  the  European Commission and the MAH on 24 June 1999 that the variation is accepted.

<div style=\"page-break-after: always\"></div>

- The  MAH  submitted  an  application  for  a  Type  I  variation  in  accordance  with  Commission Regulation (EC) No. 542/95 for the the scale up of the hepatitis B component of Twinrix Adult. The EMEA adopted a positive opinion on 29 July 1999 and no amendments to the Annexes of the Community Marketing Authorisation were required.
- The  MAH  submitted  an  application  for  a  Type  I  variation  in  accordance  with  Commission Regulation (EC) No. 542/95 for the to the implementation of a new working seed for hepatitis B component of Twinrix Adult. The EMEA adopted a positive opinion on 29 July 1999 and no amendments to the Annexes of the Community Marketing Authorisation were required.
- The  MAH  submitted  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  an application for a Type I variation for an additional packaging site located in Germany (Bönen), in addition to the packaging sites located in Belgium (Rixenart, Wavre) and France (Mayenne). The EMEA notified the European Commission and the MAH on 31 May 2000 that the variation is accepted.
- The  MAH  submitted  an  application  for  a  Type  I  variation  in  accordance  with  Commission Regulation  (EC)  No.  542/95  relating  to  a  change  in  the  HBsAg  specifications  and  analytical methods. The EMEA adopted a positive opinion on 29 June 2000 and no amendments to the Annexes of the Community Marketing Authorisation were required.
- The  MAH  submitted  an  application  for  a  Type  I  variation  in  accordance  with  Commission Regulation  (EC)  No.  542/95  for  the  scale-up  of  the  manufacture  of  the  active  substance, inactivated  hepatitis  A  virus  (HAV), which is  one of the active substances of Twinrix Adult. The  EMEA  adopted  a  positive  opinion  on  21  September  2000  and  no  amendments  to  the Annexes of the Community Marketing Authorisation were required.
- The  MAH  submitted  an  application  for  a  Type  II  variation  in  accordance  with  Commission Regulation  (EC)  No.  542/95  to  add  the  wording  regarding  sensitization  to  thiomersal  in medicinal products as agreed by CPMP in July 1999 in section 4.4 of SPC. The EMEA adopted a positive opinion on 19 October 2000 and the amendments to Annexes I and IIIB (Summary of Product Characteristics and Package Leaflet) of the Community Marketing Authorisation were adopted on 13 March 2001.
- The  MAH  submitted  an  application  for  a  Type  II  variation  in  accordance  with  Commission Regulation (EC) No. 542/95 for the to the approval of a new MRC-5 Manufacturers Working Cell Bank, in replacement of the currently used MRC-5 Manufacturer Working Cell Bank, for the production of inactivated hepatitis A virus bulk antigen, which is used for the formulation of Twinrix  vaccines.  The  EMEA  adopted  a  positive  opinion  on  14  December  2000  and  no amendments to the Annexes of the Community Marketing Authorisation were required.
- The MAH submitted in accordance with Article 10(3)  of  Council  Directive  No.  92/27/EE,  a notification of a change to an aspect of the Package Leaflet not connected to the Summary of Product  Characteristics.  The  EMEA  notified  the  European  Commission  and  the  MAH  on  20 March 2001 that the change is accepted. The Commission Decision amending the Community Marketing Authorisation was adopted on 17 May 2001.

<div style=\"page-break-after: always\"></div>

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                                                                                                                                                                                                                                                                                                    | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amen ded on   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|------------------------------------------|
| Quality change (demonstration of TSE compliance)                                                                                                                                                                                                                                                                                                         | II/0018              | II                       | 20.09.01                            | 20.10.01                                 |
| Update of the SPC (sections 4.2 and 5.1) following a new vaccination schedule                                                                                                                                                                                                                                                                            | II/0019              | II                       | 26.04.01                            | 30.08.01                                 |
| Renewal                                                                                                                                                                                                                                                                                                                                                  | R/0020               | R                        | 26.07.01                            | 09.11.01                                 |
| Change in name of manufacturing site                                                                                                                                                                                                                                                                                                                     | I/0021               | I                        | 16.11.01                            | -                                        |
| Change in the name of theMAH and manufacturer responsible for batch release                                                                                                                                                                                                                                                                              | I/0022               | I                        | 05.11.01                            | 17.12.01                                 |
| Change in name of manufacturing site                                                                                                                                                                                                                                                                                                                     | I/0023               | I                        | 16.11.01                            | -                                        |
| Update of the SPC (section 4.8 undesirable effects) following a review of the post-marketing surveillance data. (7th PSUR).                                                                                                                                                                                                                              | II/0024              | II                       | 17.01.02                            | 11.04.02                                 |
| Change(s) to test methods and/or specifications for the finished product                                                                                                                                                                                                                                                                                 | II/0025              | II                       | 21.03.02                            | 03.04.02                                 |
| Amendment of the Package Leaflet to reflect changes in section 4.8 of the SPC, previously approved through the variation EMEA/H/C/112/II/24. In addition, the name and address of the local representatives in Greece, Spain, Italy, Norway and the United Kingdom have been updated.                                                                    | II/0026              | II                       | 27.06.02                            | 24.10.02                                 |
| Change(s) to manufacturing process for the active substance                                                                                                                                                                                                                                                                                              | II/0027              | II                       | 25.07.02                            | 02.09.02                                 |
| Change(s) to shelf-life of the active substance                                                                                                                                                                                                                                                                                                          | II/0028              | II                       | 25.07.02                            | 02.09.02                                 |
| Change(s) to test methods and/or specifications for the active substance                                                                                                                                                                                                                                                                                 | II/0030              | II                       | 20.02.03                            | 07.03.03                                 |
| Change(s) to test methods and/or specifications for the finished product                                                                                                                                                                                                                                                                                 | II/0031              | II                       | 25.09.03                            | 03.10.03                                 |
| Change(s) to manufacturing process for the active substance                                                                                                                                                                                                                                                                                              | II/0032              | II                       | 22.10.03                            | 27.10.03                                 |
| Change(s) to manufacturing process for the active substance                                                                                                                                                                                                                                                                                              | II/33                | II                       | 22.10.03                            | 27.10.03                                 |
| Addition of a manufacturing site for part of the manufacturing process                                                                                                                                                                                                                                                                                   | I/35                 | I                        | 18.07.03                            | -                                        |
| The MAHproposes to amend section 4.4 (Special warnings and special precaution of use) of the Summary of Product Characteristics (SPC) to reflect the factors that may lead to a reduced hepatitis B immunogenicity. The PL has been amended accordingly. In addition, the contacts of the DE, ES, IR, PT and FI local representatives have been amended. | II/0036              | II                       | 20.11.03                            | 30.01.04                                 |

1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application.

T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.